Celiva provides a non-invasive saliva-based screening test for celiac disease, utilizing a multi-biomarker approach for improved accuracy and rapid results. This accessible and cost-effective solution aims to shorten the diagnostic odyssey for patients and facilitate earlier intervention.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic pathways for celiac disease are invasive, costly, and time-consuming, often leading to prolonged periods of undiagnosed symptoms and associated health complications. This delay in diagnosis contributes to significant patient suffering and increased healthcare resource utilization.
Solution
Celiva offers a non-invasive saliva-based screening test designed to improve accessibility and affordability in celiac disease diagnosis. The platform leverages a multi-biomarker approach to enhance diagnostic accuracy, providing rapid results that expedite the identification of potential celiac disease cases. By simplifying the initial screening process, Celiva aims to reduce the diagnostic odyssey for affected individuals and facilitate earlier intervention.
Target Audience
Primary customers include individuals seeking celiac disease screening, primary care physicians, and gastroenterologists looking for an accessible and efficient initial diagnostic tool.
Features
- Non-invasive saliva sample collection for patient comfort and ease of use.
- Multi-biomarker assay for improved sensitivity and specificity in celiac disease detection.
- Rapid turnaround time for results, enabling quicker clinical decision-making.
- Cost-effective screening solution compared to traditional diagnostic methods.
- Cloud-based data management for secure storage and retrieval of test results.